Analjit Singh appointed non-executive Chairman of Max Financial Services

New Delhi: Max Financial Services, which houses the life insurance business of the $3-billion Max Group, has named its sponsor and founding shareholder Analjit Singh as nonexecutive chairman of the company in a filing to stock exchanges on Monday.

Singh said his appointment on the board was in consultation with current chairman Naina Lal Kidwai, who felt that as the ‘principal sponsor’ of the company he would be able to expedite decision-making. Kidwai will now continue in her role as an independent non-executive director of the company.

“I am heavily committed to India, to my businesses and my family,” Singh told ET, refuting what he termed ‘rhetoric’ about him giving up on his home turf.

The Max Group founder also ruled out speculation pertaining to his plans to exit the life insurance venture. “We are not going to exit the business. I will remain the single-largest principal sponsor,” he said.

Singh will take a four-point plan to the board of the financial services company on Friday to strengthen the life insurance business with a focus on building its proprietary distribution channels, he told ET.

Max Life Insurance Company is the largest non-bank private life insurer in India and contributes over two-thirds of Max Group’s revenues.

The company was separated as part of a demerger process involving erstwhile Max India, following which it became a subsidiary of the listed Max Financial Services.

Max India and Max Ventures and Industries are two other listed entities that resulted from the demerger. The former houses the group’s hospitals business and its health insurance joint venture with Britain’s Bupa, while the latter is the holding company for the packaging and real estate interests of the group.

Japan’s Mitsui Sumitomo Insurance is an investor in Max Life Insurance Company.

The group recorded consolidated revenues of Rs 19,151 crore in the year to March 2018, the company stated in its exchange filings. It employs 24,500 people.

  • Related Posts

    Yashoda Medicity’s Medical Tourism Footprint widens with Republic of Kazakhstan on Board

    MOU signed for Patient Referrals, Tele-Consultations and Specialist Healthcare Collaboration Delhi NCR: Unveiled not long ago, Yashoda Medcity’s reputation as being best in class healthcare facility in Delhi NCR has…

    Liver enters FATal Straits in India, AIIMS Experts red flag

    In first for India, World Congress of Gastroenterology comes calling to asses GI disease burden New Delhi: As global and national burden of digestive diseases reach a critical crossroads, World…

    Leave a Reply

    Your email address will not be published. Required fields are marked *

    You Missed

    Max Healthcare Foundation announces fourth edition of Max Medical Scholarship Programme

    Max Healthcare Foundation announces fourth edition of Max Medical Scholarship Programme

    CDSCO warns against sales of unauthorised toxic cosmetics products from Pakistan

    CDSCO warns against sales of unauthorised toxic cosmetics products from Pakistan

    Large stock of counterfeit medicines seized from private facility in Bengaluru

    Large stock of counterfeit medicines seized from private facility in Bengaluru

    Punjab’s Drugs Challenge Shifts, Other States Blamed For Pharma Smuggling

    Punjab’s Drugs Challenge Shifts, Other States Blamed For Pharma Smuggling

    Spurious drug probe: SIT raids medical store in Bengaluru, detains proprietor

    Spurious drug probe: SIT raids medical store in Bengaluru, detains proprietor

    US FDA grants orphan drug designation for Lundbeck’s investigational anti-ACTH monoclonal antibody asedebart to treat endogenous Cushing’s syndrome

    US FDA grants orphan drug designation for Lundbeck’s investigational anti-ACTH monoclonal antibody asedebart to treat endogenous Cushing’s syndrome